Introduction
During the last few decades, analyses of chiral drugs have been growing in pharmaceutical, agrochemical and food industries and other analytical laboratories due to different pharmaceutical activities of the enantiomers. It is well known that one of the enantiomers is biologically active, whereas the other may be toxic, inactive or ballast (1) . The United States Food and Drug Administration (FDA), European Committee for Proprietary Medicinal Products, Health Canada and Pharmaceutical and Medical Devices Agencies of Japan have banned the marketing of all racemic drugs (2, 3) . Therefore, the chiral analyses of racemic drugs in biological samples are important for developing and designing safe medication. Out of 200 most popular and prescribed drugs, approximately 120 are chiral in nature (4) . The curing action of chiral drugs in humans and other organisms involves stereoselective absorption, distribution, metabolism and excretion phenomena. The fate of chiral drugs in biological systems can be studied by monitoring their enantiomeric ratio during various biological processes. This information may be used to design and develop safe chiral drug medications (5) . For example, racemic thalidomide is dangerous to the fetus a pregnant woman is carrying because it is teratogenic; hence, the (þ)-enantiomer is prescribed as the safe one. Unfortunately, it racemizes in the body, giving rise to the ( -)-antipode, resulting in teratogenicity in the fetus (6) . Similarly, other homochiral drugs can racemize, producing other serious side effects and problems.
Some analytical techniques have been developed to monitor the chiral ratio of these drugs in biological samples. Among them, liquid chromatography, especially high-performance liquid chromatography (HPLC), has achieved a good reputation in chiral separation science. Various chiral selectors used in HPLC columns include polysaccharide, macrocyclic glycopeptide antibiotics, cyclodextrin, proteins, crown ethers and ligand exchanges. The chiral analyses of racemic drugs in biological samples is a tedious job because of the low amount of drugs and the presence of thousands of impurities, which need specific, reproducible and effective sample preparation methods. One of the most important trends to simplify these complications is the generation of simple, rapid and reliable procedures for sample preparations. The sample preparation includes many steps: sample collection, preservation, filtration, digestion/homogenization and finally, extraction. The liquid -liquid extraction (LLE) method has been used as the predominant sample preparation technique for some decades, but it has been replaced by the solid-phase extraction (SPE) method (7) . A literature survey indicates few reviews on chiral separations of drugs in biological samples (8 -14) . These reviews do not describe the sample preparation technique, which is the most important aspect in chiral biomedical analyses. SPE has certain advantages over LLE, such as inexpensiveness, rapidity, selectiveness and reproducibility (15, 16) . In view of these facts, attempts have been made to describe the recent developments of the analyses of chiral drugs in biological samples by using SPE and chiral HPLC methods. For this purpose, a thorough search of the literature was conducted by analytical abstracts, Scopus, Science Direct and PubMed. The present article describes the applications of SPE and chiral HPLC in enantioselective analyses of racemic drugs in biological samples. Efforts have been made to discuss selected SPE chiral HPLC methods, types of chiral selectors and drugs, chiral recognition mechanisms and future perspectives.
Scope
The scope of chiral analyses in biological samples depends on the knowledge of different pharmaceutical activities of the enantiomers. Additionally, the stereoselective fate of optically active drugs during metabolism has also compelled scientist to monitor their chiral ratio. In addition to this, racemization of optically active drugs in biological samples requires enantioselective analyses. The literature search revealed that some work has been conducted on chiral separations by HPLC. None of these contains a discussion on sample preparation methods. Therefore, there is an urgent need for a review article with detailed information on sample preparation and chiral separation by SPE and HPLC for the analyses of drugs in biological samples. In view of these facts, the discussion has been divided into two parts; i.e., sample preparation and chiral chromatography. Regarding sample preparation, SPE methods have been discussed, whereas chiral HPLC was selected as the chromatographic modality.
Chiral Drugs
As discussed previously, among the 200 most frequently prescribed and used drugs, approximately 60% are chiral in nature. Therefore, many pharmaceutical industries started to market the optically active pure enantiomer of some drugs (17 -22) . The most important chiral drugs belong to anti-inflammatory, antiviral, anticancer, anticholinergic, antibiotic, antidiabetic, antigastric, antidepressant, antisedative, antiepileptic, and cardiovascular, lipid regulating, steroid, calcium channel blocking, analgesic and folic acid analogs (23) . The debate of racemics versus enantiomers resulted in a new market strategy, the so-called racemic switch. A racemic switch stands for the development of a single enantiomer from a drug that was earlier approved as a racemate. The worldwide consumption of chiral drugs in 1993 was only 33 billion U.S. dollars, which increased to 73 billion U.S. dollars in 1997, followed by 172 billion U.S. dollars in 2002 (24). Furthermore, according to Bingyun and Haynie, the consumption cost of single enantiomers was expected to increase up to 200 billion dollars in 2008 (25) .
Sample Preparation by SPE
In the analyses of chiral drugs, sample preparation is an integral part that allows the simplification of the matrix. This includes the removal of proteins and other impurities, and desalting (26) . The analyses of chiral drugs in biological samples are problematic and tedious jobs because many impurities are present. The most commonly analyzed biological samples for chiral drugs are plasma and urine. Previously, sample preparation was considered to be the longest methodology, but recent advancements such as the development of SPE have reduced this step to a narrow experimental band. Approximately 80% of the chromatographers of the world are using SPE methods (15) . Various cartridges and discs are available for this purpose and their selection depend on the type of drugs and experimental conditions. The current state-of-the-art of the sample preparation of chiral drugs before loading them onto the HPLC machine is summarized in the following subsections.
Blood
The chiral analysis of drugs in blood involves the coagulation and separation of the plasma. The plasma proteins are removed by precipitation, followed their separation. In SPE, the pH of plasma is adjusted with suitable buffer and passed through the SPE cartridge. The ingredients are extracted with suitable solvents. The selection of the buffer depends on the types of drugs. Basically, pH and buffer concentration are determined in such a way that the drug molecules may interact with the material of the cartridge. Many materials are available for SPE cartridges, but silica gel is the most commonly used. Additionally, the maximum drug extraction is optimized by varying other SPE parameters such as the flow rates of the buffer (containing drug) and eluting solvents, choice of eluting solvents and temperature.
Liu and de Stewart (27) described a C 18 SPE procedure for analyzing R-and S-promethazine enantiomers from human plasma. The working buffer and eluting solvent were phosphate and acetonitrile -triethylamine (100:2, v/v). Furthermore, the same group (28) developed SPE methods for the sample preparation of ondansetron enantiomers in human serum. The SPE cartridge used was cyanopropyl silica gel. The enantiomers were eluted by methanol containing 0.1% triethylamine. Glowka (29) extracted racemic flurbiprofen and indobufen from serum (0.2 mL) by SPE (octadecyl silica gel). Lanchote et al. (30) compared the extraction of R-and S-enantiomers of metoprolol in human plasma by using LLE and SPE (C 18 ) methodologies. Tetraborate and methanol were used as the buffer and eluting solvent, respectively. The authors described SPE as a better technique than the LLE method. Dodd et al. (31) prepared human plasma samples by SPE for the chiral analyses of enantiomers of mirtazapines. Phosphate buffer and methanol were used as the working buffer and eluting solvent.
Zhu and Neirinck (32) reported the extraction of the R-and S-enantiomers of baclofen in human plasma on a C 18 silica gel SPE cartridge. The buffer and eluting solvents were phosphate and methanol, respectively. Aboul-Enein and Ali (33) described SPE sample preparation for the enantiomers of cromakalim in human plasma by using a C 18 Sep-Pak cartridge. The buffer used was phosphate (50 mM, pH 3.0) and the enantiomers were eluted with pure methanol. Martens et al. (34) described the SPE extraction of omeprazole with D 3 -omeprazole as the internal standard. The SPE cartridge was made of C 18 silica gel. Siluk et al. (35) described an SPE method for the sample preparation of (R, R)-fenoterol in rat plasma prior to chiral analyses. (R, R)-Fenoterol was extracted from 125 mL of plasma using a Bond Eluta Plexa cartridge of HILIC silica. The adsorbed racemic compound was extracted by a 2.0 mL mixture of ethyl acetate-methanol (1:1, v/v). Xu and Musson (36) described an SPE methodology for the separation of MK-0974 in human plasma on an Oasis Elution HLB 96 cartridge using 400 mL of 10% acetonitrile. Liu et al. (37) developed a fast and selective SPE method for the determination of 6R-leucovorin, 6S-leucovorin and 5-methyl tetrahydrofolate (5-MeTHF) in human plasma by using Oasis HLB C 18 cartridges. The working buffer was ammonium acetate. The elution was conducted by 1.0 mL methanol containing 50.0 mg/mL of ascorbic acid and 50.0 mg/mL of 2-mercaptoethanol. Martin et al. (38) compared the extraction of b-blockers from plasma using a molecular imprinted polymer. According to the authors, the molecular imprinted polymer method represented no advantage over the C 18 SPE method.
Urine
Comparatively, urine is less complicated than plasma and needs a less rigorous sample preparation procedure. Normally, proteins are absent in urine and SPE is better suited for the extraction procedure. The most important parameter in the sample preparation of urine is pH, which is adjusted as per the properties of the analytes being extracted. Much work has been conducted on urine sample preparation by SPE for simple analyses, but only few papers are available regarding chiral separations.
Ponder and Stewart (39) described a C 18 SPE sample preparation for R-and S-promethazine in urine. Phosphate buffer (0.1M, 6.0 pH) and 2.0% ammonium hydroxide in ethanol were used as the working buffer and eluting solvent, respectively. Asafu-Adjaye and Shiu (40) developed a C 8 SPE method for the determination of verapamil enantiomers in urine. Phosphate buffer (0.03M, pH 10.0) was used as the working solution and methanol was used for extraction. The percentage of extraction recoveries was 85% at a 3.0 ng/mL concentration of the analytes. de Oliveira et al. (41) reported a solid-phase microextraction sample preparation method for ibuprofen metabolites in human urine. The mobile phase was hexane-isopropanol (95:5, v/v) with 0.05% trifluoroacetic acid on a Chiralpak AS column. The relative extraction efficiencies of carboxyibuprofen (COOHIbu) and 2-hydroxyibuprofen (2-OHIbu) stereoisomers on PDMS/DVB and CW/TPR fiber coatings are shown in Figure 1 . The figure shows that the extractions of COOHIbu stereoisomers were higher on CW/TPR than PDMS/DVB fibers. Contrarily, the extraction of 2-OHIbu stereoisomers was more efficient on PDMS/DVB than CW/TPR fibers. Furthermore, the effects of various parameters on the extraction of these stereoisomers on CW/TPR fibers are shown in Figure 2 . This figure shows that the maximum extraction was achieved at 45 min, 6.0, 608C and 20% as extraction time, pH, temperature and sodium chloride concentration, respectively. These authors also studied the desorption time of these stereoisomers from the CW/TPR fiber ( Figure 3 ). It is clear from this figure that 5 min was a suitable time to achieve maximum desorption. The SPE conditions for sample preparation of some chiral drugs in plasma samples are summarized in Table I .
Chiral Separation by HPLC
Among some methods, liquid chromatographic modalities are the primary choice for chiral separations due to their wide range of applications, ease of operation, selectivity, efficiency and reproducibility. Chiral HPLC has achieved a good reputation in the area of enantio-resolution due to the availability of a wide range of chiral stationary phases (CSPs). The different CSPs available are based on various chiral selectors such as polysaccharides, cyclodextrins, macrocyclic glycopeptide antibiotics, proteins, crown ethers, ligand exchangers, Pirkle's types and several others (1, 42) . Among these, polysaccharide CSPs are the best because they are highly selective, sensitive and reproducible (42) . Zhang et al. (43) reported that more than 95% of racemic compounds have been resolved successfully on these CSPs in chromatographic techniques. The chiral separations of different drugs and pharmaceuticals in biological samples have been categorized based on the type of CSP and discussed in the following subsections.
Polysaccharides CSPs
These CSPs are made by various derivatives of cellulose and amylose molecules. It has been observed that amylose is better than cellulose because the former is more helical than later (44) . They are available in various trade names by different vendors; some of these phases used in chiral separations in biological samples are discussed herein. Ascalone et al. Liu and Stewart (28) described the analysis of ondansetron enantiomers in human serum on a Chiralcel OD-R column. The mobile phase was 0.7M sodium perchlorate-acetonitrile (65:35, v/v). The authors reported a 200 ng/mL recovery for both enantiomers of ondansetron. Intra-day and inter-day relative standard deviation (RSD) precisions were in the ranges of 0.3 -5 and 2 -8% for each of the enantiomers, respectively. The linear range was 15-750 ng/mL for both enantiomers in serum. The limit of detection (LOD) and LOQ were 15.0 and 7.0 ng/mL, respectively. Adjaye and Shiu (40) also used a Chiralcel OD-R column for the enantiomeric resolution of verapamil and norverapamil. The reported LOD was 3.0 ng/mL, with 2.5-300 ng/mL as the range of linearity. The intra-day and inter-day reproducibilities were 10.5-14.2 and 4.8-9.3%, respectively. Kaddoumi HPLC method for the enantiomeric resolution of atenolol in biologic fluids on a Chiralcel OD-H column. The mobile phase was hexane-ethanol (85:15, v/v) with 0.1% diethylamine. According to the authors, RSDs from nominal values were lower than 10% for both within-day and between-day assays. The results showed that there no statistically significant differences among variation in days. The LOQ was 10.0 ng/mL, with 10-5,000 ng/mL as the linear range for both methods. Lanchote et al. (30) used Chiralcel OD-H and Chiralpak AD columns for the enantioselective analysis of metoprolol in plasma. The author used plasma from healthy Caucasian volunteers and reported Chiralpak AD to be a better column than the Chiralcel OD-H. de Santana et al. (48) evaluated the chiral resolution of mirtazapine in human plasma by using a Chiralpak AD column. The mobile phase was hexane-ethanoldiethylamine (98:2: 0.1, v/v). According to the author, the LOQ was 5.0 ng/mL for within-day and between-day assays. The precision and accuracy were achieved at three different concentration levels, i.e., 10, 50 and 250 ng/mL. Furthermore, the same group (27) described the quantitation of promethazine Figure 4 . This figure indicates a small peak of ( -)-enantiomers, which is attributable to its strong binding with plasma proteins; this is why ( -)-chromakalim is pharmacologically active.
Xu and Musson (36) reported the chiral separation of MK-0974 in human plasma by using a Chiralcel OJ-RH column (150 Â 4.6 mm) with a mass spectrometry detector. According to the authors, the addition of ammonium trifluoroacetate to the organic mobile phase improved detection sensitivity more than 30 fold. The quantification of four stereoisomers in human plasma was validated over the concentration range of 0. ) discussed the enantioselective determination of acebutalol and its active metabolite diacetolol in spiked human plasma on a CBH column (chiral-CBH) with mass spectrometry detection. According to the authors, three separate batches were analyzed under optimal mobile phase conditions. The validation of the method was conducted in a range of 0.0500-50.0 ng/mL for each enantiomer using 0.100 mL of plasma sample. The intra-day and inter-day precision and accuracy of the quality control at low, medium and high concentration levels showed 4.5% as RSD, along with relative errors of 8.7-5.6% for individual enantiomers. Ali et al.
(51) described the chiral analysis of b-adrenergic blockers in human plasma. The SPE of alprenolol, carazolol, metoprolol and oxprenolol from human plasma was achieved on C 18 cartridges using phosphate buffer (50 mM, pH 9.0), followed by elution with methanol containing 0.1% acetic acid. Chiral HPLC was conducted on a CelluCoat [tris-(3,5-dimethylphenyl) carbamate cellulose] column using different combinations of n-heptaneethanol-diethylamine at flow rates of 1.0 and 2.0 mL/min. The detection was achieved at 225 nm with 27 + 18C as the working temperature. The chromatographic parameters, i.e., k, a and Rs factors, ranged from 0.26 to 10.64, 1.12 to 2.10 and 1.05 to 2.26, respectively. Al-Othman and Ali (52) and R, S-hyoscyamine in human plasma using a Chirobiotic V column. The mobile phase was methanol-acetic acid -triethylamine, which was varied from 100:0.05:0.04 to 100:0.05:0.1 (v/v/v). The author used R, S-propranolol-d 7 as the internal standard. The intra-day and inter-day precision and accuracy were 13.2 and 10.2%, respectively. The assay was used to analyze plasma samples from seven subjects who had received intravenous infusions of R, S-propranolol and R, S-hyoscyamine. Hefnawy and Aboul-Enein (54) described a chiral HPLC method for the determination of vesamicol enantiomers in human plasma on a Chirobiotic V column. The mobile phase was methanol-glacial acetic acid-triethylamine (100:0.1:0.05, v/v). The method proved to be precise (within-run precision ranged from 1.3 to 2.7% and between-run precision ranged from 1.5 to 3.4%) and accurate (within-run accuracy ranged from 0.8 to 3.4% and between-run accuracy ranged from 1.7 to 5.0%). The LOQ and LOD for each enantiomer in human plasma were 1.0 and 0. According to the authors, the average extraction recovery was 81.6% for R-(2)-baclofen, 83.0% for S-(1)-baclofen and 94.0% for the internal standard (p-aminobenzoic acid). The LOQ for both R-(2)-and S-(1)-baclofen in human plasma was 20 ng/mL. Ponder and Stewart (39) described an HPLC method for the determination of promethazine enantiomers in human urine and serum on a brush-type column. The mobile phase was hexane-1,2-dichlorethane-ethanol-trifluoroacetic acid (400:150:100:1, v/v). According to the authors, chlorpromazine was used as the internal standard for urine analysis. The ratio of drug to internal standard was linear from 0.25 to 10 ng/mL in urine and 2 to 10 ng/mL in serum. Barker et al. 
Chiral Recognition Mechanism
Ali et al. (44) described the mechanism of chiral recognition on several CSPs. According to these authors, the chiral selectors have special types of structures such as grooves, baskets or cavities in which enantiomers become stereospecifically trapped. The trapping of enantiomers is stabilized by various forces. The most important forces are hydrogen bonding, p-p interactions, coordination bonding, electrostatic force of attraction, van der Waal forces, steric effects, dipole induced dipole attraction and dispersive forces. The combination of these forces is entirely different in each chiral selector. The chiral recognition mechanisms are based on a key and lock arrangement system. Basically, the enantiomers fit sterogenically into the chiral grooves at different extents and mobile phases try to elute them. As a result of these combined effects, the enantiomers elute at different time intervals.
Future Perspectives
The future of optically active drugs for humans is a very important issue that requires sensitive, selective and reproducible sample preparation and HPLC methods. Currently, people all over the world are interested in the stereoselective bindings of enantiomers and their metabolites and the effects on the human body. Therefore, the development of chiral drugs is increasing day by day. Many pharmaceutical companies have started to manufacture and market optically active pure drugs. Now is the time to replace racemic drugs by enantiopure homochiral drugs. However, these require the complete state-of-the-art chiral analyses of racemic drugs in biological samples. Therefore, there is a great need to develop SPE-chiral-HPLC methodologies for all prescribed racemic and homochiral drugs. More emphasis should be placed on microextraction by using hollow fiber technology, because detection is required at nano and pico levels. This task may be achieved by the newly developed nano liquid chromatography (NLC) and nano capillary electrophoresis (NCE) techniques (7) . Additionally, online hyphenation is an essential requirement to avoid complicated sample preparation techniques. All chiral chromatographers should extend their work in real biological samples by using chiral hyphenated NLC and NCE. These methods will be highly useful in developing optically active medications. In addition, chiral hyphenated NLC and NCE techniques are capable of unlocking many mysteries in genomic and proteomic research.
Conclusion
The chiral analyses of recent racemic drugs in biological samples are currently required. This article illustrates only a few available papers concerning this issue. There continues to be a great demand for the development of SPE-chiral-HPLC methodologies for the analyses of all racemic drugs. Before prescribing such medications chiral profiles should be available, especially regarding their racemization and the fates of their metabolites. To date, ample work has not been conducted in this direction. The replacement of all racemic medication by homochiral drugs should continue to be an international goal of pharmaceutical companies.
